Skip to main content
S&P 5007,592.40-0.35%DOW52,297.09-0.36%NASDAQ25,366.09-0.39%BTC$69,679.00-4.05%ETH$1,973.62-2.01%GOLD$3,899.30+0.36%OIL$88.64-0.11%
Smart Investors Daily
SID Premium
CO

NASDAQ · CORT

Corcept Therapeutics Incorporated

Healthcare · Biotechnology

$73.71

Down-$0.82 (-1.10%)

Updated Nov 13, 2026, 1:36 PM

SID Score

4.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.17B
P/E ratio
85.77
Dividend yield
0.00%
52-week range
$28.66 – $126.38
Volume
847.07K
Avg. volume
846.24K

Price performance · CORT

CORT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

CORT closed at $73.71 after 21 trading sessions, down 34.98% for the selected period.

Last close
$73.71
Period change
-34.98%
Period low
$71.63
Period high
$116.45
Daily close
View OHLC price history
CORT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$72.23$75.495$72.23$73.71847.07K
Nov 11, 2026$74.39$75.92$73.72$74.531.12M
Nov 10, 2026$74.07$76.495$71.57$73.351.34M
Nov 9, 2026$73.31$76.58$70.5125$75.0251.65M
Nov 6, 2026$73.60$74.86$72.17$72.771.41M
Nov 5, 2026$77.88$78.9889$71.515$71.631.51M
Nov 4, 2026$84.98$84.98$71.29$79.222.2M
Nov 3, 2026$80.92$84.19$80.92$81.931.52M
Nov 2, 2026$80.93$82.23$79.395$80.461.59M
Oct 30, 2026$85.00$85.305$80.28$81.121.43M
Oct 29, 2026$86.07$88.01$85.21$85.951.19M
Oct 28, 2026$86.43$88.59$86.00$86.281.05M
Oct 27, 2026$85.31$87.97$84.91$87.59925.52K
Oct 26, 2026$86.10$91.78$85.86$87.1251.87M
Oct 23, 2026$106.05$106.0925$84.13$85.863.1M
Oct 22, 2026$115.16$115.73$107.3269$107.50809.88K
Oct 21, 2026$116.45$118.42$116.10$116.28516.77K
Oct 20, 2026$112.60$117.135$111.955$116.45549.57K
Oct 19, 2026$111.70$113.09$110.50$112.10392.85K
Oct 16, 2026$113.17$113.635$107.7902$110.16849.97K
Oct 15, 2026$116.31$117.4792$113.0201$113.37668.52K

Latest CORT news

The latest Smart Investors Daily articles mentioning CORT.

Stock researchCompany · Overview

CORT research

Overview

Company profile and research snapshot.

Company profile

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$140.00
Implied upside
—
Analysts
—
CORT recent ratings
DateFirmRatingTarget
Nov 4, 2026Piper SandlerOverweight—
Sep 18, 2026HC Wainwright & Co.Buy—
Jul 30, 2026Canaccord GenuityBuy—
Jul 30, 2026Piper SandlerOverweight—
Jul 30, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build

Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That profit jump landed against a sharp reset in sentiment, with Corcept Therapeutics’ share price down 40.11% over the past month and 35.33% over 90 days, even after an 87.51% year-to-date share price gain and a 186.18% three-year total shareholder return that points to strong long-run backing for the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By